Finland · Delayed Price · Currency is EUR Scanfil Oyj Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw strong revenue and margin growth, driven by the MB Elettronica acquisition and robust organic expansion. All regions contributed positively, with Energy & Cleantech and Aerospace & Defense segments showing notable momentum. Guidance for 2026 is reaffirmed.
-
The acquisition expands presence in Southern Europe, diversifies the customer base, and strengthens exposure to high-growth sectors like aerospace and defense. Financial terms include a €123 million valuation with an earn-out, and integration is supported by recent capacity investments.
Fiscal Year 2025
-
Q4 2025 saw robust organic growth, major acquisitions, and capacity expansions, driving a 40% EPS increase and a proposed dividend hike. Guidance for 2026 is positive, with integration of new entities and continued organic growth as key priorities.
-
Revenue grew over 10% year-over-year to EUR 191.3 million, with strong organic and acquired growth, robust EBITDA, and major contract wins in MedTech, Life Science, and logistics. Strategic acquisitions and investments in the US and Malaysia support future expansion.
-
Q2 saw 3.4% revenue growth and a 7% EBITDA margin, with strong performance in Americas and APAC, and positive momentum in industrial, medtech, and defense segments. Recent acquisitions and a robust pipeline support a positive outlook, with organic growth expected to turn positive in H2.
-
The acquisition brings a strong aerospace and defense portfolio, expands reach into Southern Europe, and adds four specialized factories. Financial terms include a €73–123 million price based on performance, with integration focused on growth and leveraging synergies.
-
The acquisition expands North American operations, doubling aerospace and defense revenue and enhancing prototyping and PCB capabilities. Financial terms include an 80% stake for EUR 13.6 million, with the seller retaining 20%. Integration will begin post-regulatory approval in Q3.
-
Celebrating its 50th anniversary, the company updated its strategy in 2024 to focus on growth, efficiency, and empowerment, while navigating a challenging year marked by customer inventory adjustments. Despite revenue headwinds, margins held steady, investments continued, and ESG progress accelerated.
-
Q1 2025 saw stable margins and strong cash flow despite a slight revenue decline, with APAC and Americas regions driving growth. Investments in Malaysia and a robust pipeline in Energy & Cleantech and Medtech & Life Science support a positive outlook for the year.
Fiscal Year 2024
-
Q4 delivered strong margins and record deal wins in Medtech and Life Science, despite a 4% revenue decline year-over-year. Full-year 2024 saw robust cash flow, reduced inventory, and a strengthened balance sheet, with 2025 guidance projecting renewed growth and continued focus on operational efficiency.
-
Q3 saw EUR 41.7 million in new contracts and resilient 7.2% margins despite an 18.6% revenue drop. The acquisition of SRXGlobal expands reach, while strong cash flow and improved inventory position support a positive outlook for Q4 and beyond.
-
The acquisition of SRX Global expands the company’s Asia Pacific footprint, diversifies its customer base, and aligns with strategic growth objectives. Financial terms include an initial EUR 23.3 million payment and an earn-out based on profitability. Synergies are expected in supply chain and customer growth.
-
Revenue fell 19.7% year-over-year to EUR 195.5 million, but operating profit margin held at 7.1% due to strong cost controls and efficiency gains. New project wins and positive cash flow strengthened the financial position, with MedTech and Life Science showing early signs of recovery.